Craniosynostosis, the premature fusion of cranial sutures, may be associated with raised intracranial pressure (ICP) with or without a reduced intracranial volume. Regardless of the aetiology, raised ICP may result in optic neuropathy, the timely detection of which can prevent further visual deterioration. Raised ICP is usually treated with craniofacial surgery such as cranial vault expansion. In this case study, we recorded serial pattern reversal visual evoked potentials (pVEPs) and obtained digital optic disc images before and after cranial vault expansion surgery. The amplitude of the pVEPs continued to decrease after cranial vault expansion surgery, prompting further neuroimaging that implicated a blocked ventriculo-peritoneal shunt. Only after shunt revision did the pVEP amplitude increase. Throughout the monitoring period, there was no change in the appearance of either the right or left optic disk, nor a consistent change in visual acuity.

Keywords:
Visual evoked potential, Optic neuropathy, Craniosynostosis
1.
Hertle RW, Quinn GE, Minguini N, Katowitz JA: Visual loss in patients with craniofacial synostosis. J Pediatr Ophthalmol Strabismus 1991;28:344–349.
2.
Mursch K, Brockmann K, Lang JK, Markakis E, Behnke-Mursch J: Visually evoked potentials in 52 children requiring operative repair of craniosynostosis. Pediatr Neurosurg 1998;29:320–323.
3.
Fok H, Jones BM, Gault DG, Andar U, Hayward R: Relationship between intracranial pressure and intracranial volume in craniosynostosis. Br J Plast Surg 1992;45:394–397.
4.
Tuite GF, Chong WK, Evanson J, Narita A, Taylor D, Harkness WF, Jones BM, Hayward RD: The effectiveness of papilledema as an indicator of raised intracranial pressure in children with craniosynostosis. Neurosurgery 1996;38:272–278.
5.
Campbell JW, Albright AL, Losken HW, Biglan AW: Intracranial hypertension after cranial vault decompression for craniosynostosis. Pediatr Neurosurg 1995;22:270–273.
6.
Rizzo PA, Pierelli F, Pozzessere G, Sancesario G, Boatta M, Santarcangelo G: Pattern visual evoked potentials in pseudotumor cerebri. A longitudinal study. Acta Neurol Belg 1984;84:57–63.
7.
Sorensen P, Trojaborg W, Gjerris F, Krogsaa B: Visual evoked potentials in pseudotumor cerebri. Acta Ophthalmol Suppl 1985;173:62–64.
8.
Krogsaa B, Soelberg Sorsensen P, Seedorff HH, Trojaborg W, Gjerris F: Ophthalmic prognosis in benign intracranial hypertension. Acta Ophthamol Suppl 1985;173:62–64.
9.
Falsini B, Tamburrelli C, Porciatti V, Anile C, Porrello G, Mangiola N: Pattern electroretinograms and visual evoked potentials in idiopathic intracranial hypertension. Ophthalmologica 1992;205:194–203.
10.
Harding GF, Odom JV, Spileers W, Spekreijse H: Standard for visual evoked potentials 1995. The International Society for Clinical Electrophysiology of Vision. Vision Res 1996;36:3567–3572.
11.
Thompson DA, Kriss A, Taylor D, Russell-Eggitt I, Hodgkins P, Morgan G, Vellodi A, Gerritsen EJ: Early VEP and ERG evidence of visual dysfunction in autosomal recessive osteopetrosis. Neuropediatrics 1998;29:137–144.
12.
Taylor WJ, Hayward RD, Lasjaunias P, Britto JA, Thompson DN, Jones BM, Evans RD: Enigma of raised intracranial pressure in patients with complex craniosynostosis: The role of intracranial venous drainage. J Neurosurg 2001;94:377–385.
13.
Gonsalez S, Hayward R, Jones B, Lane R: Upper airway obstruction and raised intracranial pressure in children with craniosynostosis. Eur Respir J 1997;10:367–375.
14.
Cinalli G, Renier D, Sebag G, Sainte-Rose C, Arnaud E, Pierre-Kahn A: Chiari ‘malformation’ in Crouzon syndrome (in French). Arch Pediatr 1996;3:433–439.
15.
Renier D, Sainte-Rose C, Marchac D, Hirsch JF: Intracranial pressure in craniostenosis. J Neurosurg 1982;57:370–377.
16.
Lepore FE: Unilateral and highly asymmetric papilledema in pseudotumor cerebri. Neurology 1992;42:676–678.
17.
Coupland SG, Cochrane DD: Visual evoked potentials, intracranial pressure and ventricular size in hydrocephalus. Doc Ophthalmol 1987;66:321–330.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.